Gold prices steady ahead of Fed decision; weekly weakness noted
In a challenging market environment, Rewalk Robotics Ltd (NASDAQ:LFWD) stock has recorded a new 52-week low, dipping to $1.22. According to InvestingPro analysis, the company maintains strong liquidity with a current ratio of 2.18 and is currently trading below its Fair Value. The company, known for its innovative solutions in the medical device sector, has faced significant headwinds over the past year, reflected in a stark 1-year change with a decline of -74.25%. Despite these challenges, InvestingPro data reveals impressive revenue growth of 41.92% over the last twelve months. Investors have shown concern as the stock struggles to regain momentum, with the latest price level marking a concerning milestone for both the company and its shareholders. The substantial drop over the past year highlights the volatility and the pressures faced by the industry, as well as the need for Rewalk Robotics to adapt and potentially re-strategize to navigate the current market conditions. Get access to 10+ additional exclusive ProTips and comprehensive analysis with InvestingPro.
In other recent news, Lifeward Ltd. reported preliminary financial results for the first quarter of 2025, with revenue approximately reaching $5.0 million and operating expenses estimated between $6.5 million and $6.7 million. These figures are unaudited and subject to change. The company also announced the national launch of the ReWalk 7 Personal Exoskeleton in the U.S., a device designed to assist individuals with spinal cord injuries, which received FDA clearance in March 2025. Additionally, Lifeward has appointed Mark Grant as its new CEO, effective June 2, 2025, as part of a planned leadership transition. The company continues to focus on innovation with products like the ReWalk 7, which features advancements such as cloud connectivity and customizable walking speeds. Furthermore, H.C. Wainwright reaffirmed a Buy rating for Lifeward, maintaining a $13 price target, following the company’s strategy to expand the market reach of its ReWalk Personal product. The analyst firm expressed confidence in Lifeward’s future, projecting significant revenue growth in the coming years. Lastly, Lifeward announced the departure of Chief Sales Officer Charles Remsberg, effective May 30, 2025, as a termination without cause.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.